The Indian authorities are going forward with the application of legal restrictions on the labelling of medical products that include the inadmissibility of stickers, the consequence of which will be containers pre-printed for the Indian market. A recent Central Drugs and Standards Control Organization (DSCO) circular underscored the need to conform to the new standard. Following pressure from firms and lobbying efforts led by the Indian manufacturers association (FICCI), a new circular was issued calling for an extension of the terms for application of the Drugs and Cosmetic Act equal to 3 months for pharmaceuticals and 6 months for equipment and cosmetic products. As in a previous case of food product labelling, such restrictions, which run counter to international practice, are predicted to raise a non-tariff barrier resulting in increased cost for Indian market producers effected.
(infoMercatiEsteri)Read more, in Italian